CVS Beats Q3 Earnings Estimates But Lowers Full-Year Guidance; Stock Drops Despite Solid Results

CVS Health beat Q3 earnings estimates with revenue of $89.8B and EPS of $2.21.

However, CVS lowered its full-year EPS guidance, causing the stock to drop 6%.

CVS reiterated its full-year adjusted EPS outlook of $8.50-$8.70.

CVS offers an attractive dividend yield of 3.5%.

Despite the lowered guidance, CVS' Q3 results were solid and the stock remains a buy.